JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  05/27 04:00:01 pm EDT
181.09 USD   +0.91%
05/26Legend Biotech Receives Conditional European Commission Approval for Multiple Myeloma Drug
MT
05/25JOHNSON & JOHNSON : to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting and the Janssen Oncology Strategy and Portfolio
PU
05/25Tentative $161.5M settlement reached in WVa opioid trial
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : to Participate in Citi's 2022 Virtual Healthcare Conference

01/27/2022 | 05:36pm EDT

New Brunswick, NJ (January 27th, 2022) - Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23rd, Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).

This conference call will be available to investors and other interested parties by visit the Johnson & Johnson website at www.investor.jnj.com.

A webcast and podcast replay will be available approximately 48 hours after the live webcast.

  • Media Contacts
    Stephanie Hartgrove
    (732) 524-1941

    Investor Contacts
    Sarah Wood
    (732) 524-2617

Disclaimer

Johnson & Johnson published this content on 27 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 January 2022 22:35:09 UTC.


© Publicnow 2022
All news about JOHNSON & JOHNSON
05/26Legend Biotech Receives Conditional European Commission Approval for Multiple Myeloma D..
MT
05/25JOHNSON & JOHNSON : to Provide Webcast Fireside Chat on Clinical Data to be Presented at t..
PU
05/25Tentative $161.5M settlement reached in WVa opioid trial
AQ
05/25Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA (guselkumab) and L..
AQ
05/25Nigeria Receives 4.4 Million Doses of Covid-19 Vaccines
AQ
05/24JOHNSON & JOHNSON : Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® ..
PU
05/24TRANSCRIPT : Johnson & Johnson Presents at UBS Global Healthcare Conference, May-24-2022 1..
CI
05/23Bayer's Xarelto Shows Long-Term Effect in Heart Disease Patients
MT
05/23JOHNSON & JOHNSON : New Data From Two Large Studies Reinforce Effectiveness of Dual Pathwa..
PU
05/23What We're Reading This Week
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 451 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,3x
Yield 2022 2,46%
Capitalization 477 B 477 B -
EV / Sales 2022 4,85x
EV / Sales 2023 4,56x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 181,09 $
Average target price 187,75 $
Spread / Average Target 3,68%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON5.86%476 521
NOVO NORDISK A/S-3.80%1 677 391
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098
ABBVIE INC.10.78%265 067